Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Stellar Biotechnologies in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $7.72.
Current Consensus is
The current consensus among 0 investment analysts is to n/a stock in Stellar Biotechnologies. This N/A consensus rating has held steady for over two years.
Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein in Europe, North America, and Asia. The company offers KLH, an immune-stimulating protein used in the production of various immunotherapies; and as a carrier molecule or finished injectable product in the immunodiagnostic market. It provides its KLH protein under the Stellar KLH brand. The company's products include Stellar KLH protein in various grades, formulations, custom configurations, and fill finishes for drug development and research applications, as well as KLH-based in vitro diagnostic kits for research and preclinical use. Its customers and partners comprise biotechnology and pharmaceutical companies, academic institutions, clinical research organizations, and research centers. Stellar Biotechnologies, Inc. is based in Port Hueneme, California.